Literature DB >> 24694123

Influence of polarization and a source model for dose calculation in MRT.

Stefan Bartzsch1, Michael Lerch2, Marco Petasecca2, Elke Bräuer-Krisch3, Uwe Oelfke1.   

Abstract

PURPOSE: Microbeam Radiation Therapy (MRT), an alternative preclinical treatment strategy using spatially modulated synchrotron radiation on a micrometer scale, has the great potential to cure malignant tumors (e.g., brain tumors) while having low side effects on normal tissue. Dose measurement and calculation in MRT is challenging because of the spatial accuracy required and the arising high dose differences. Dose calculation with Monte Carlo simulations is time consuming and their accuracy is still a matter of debate. In particular, the influence of photon polarization has been discussed in the literature. Moreover, it is controversial whether a complete knowledge of phase space trajectories, i.e., the simulation of the machine from the wiggler to the collimator, is necessary in order to accurately calculate the dose.
METHODS: With Monte Carlo simulations in the Geant4 toolkit, the authors investigate the influence of polarization on the dose distribution and the therapeutically important peak to valley dose ratios (PVDRs). Furthermore, the authors analyze in detail phase space information provided by Martínez-Rovira et al. ["Development and commissioning of a Monte Carlo photon model for the forthcoming clinical trials in microbeam radiation therapy," Med. Phys. 39(1), 119-131 (2012)] and examine its influence on peak and valley doses. A simple source model is developed using parallel beams and its applicability is shown in a semiadjoint Monte Carlo simulation. Results are compared to measurements and previously published data.
RESULTS: Polarization has a significant influence on the scattered dose outside the microbeam field. In the radiation field, however, dose and PVDRs deduced from calculations without polarization and with polarization differ by less than 3%. The authors show that the key consequences from the phase space information for dose calculations are inhomogeneous primary photon flux, partial absorption due to inclined beam incidence outside the field center, increased beam width and center to center distance due to the beam propagation from the collimator to the phantom surface and imperfect absorption in the absorber material of the Multislit Collimator. These corrections have an effect of approximately 10% on the valley dose and suffice to describe doses in MRT within the measurement uncertainties of currently available dosimetry techniques.
CONCLUSIONS: The source for the first clinical pet trials in MRT is characterized with respect to its phase space and the photon polarization. The results suggest the use of a presented simplified phase space model in dose calculations and hence pave the way for alternative and fast dose calculation algorithms. They also show that the polarization is of minor importance for the clinical important peak and valley doses inside the microbeam field.
© 2014 American Association of Physicists in Medicine.

Entities:  

Mesh:

Year:  2014        PMID: 24694123     DOI: 10.1118/1.4867858

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  9 in total

Review 1.  Nanotube x-ray for cancer therapy: a compact microbeam radiation therapy system for brain tumor treatment.

Authors:  Lei Zhang; Hong Yuan; Christina Inscoe; Pavel Chtcheprov; Michael Hadsell; Yueh Lee; Jianping Lu; Sha Chang; Otto Zhou
Journal:  Expert Rev Anticancer Ther       Date:  2014-12       Impact factor: 4.512

2.  Non-conventional Ultra-High Dose Rate (FLASH) Microbeam Radiotherapy Provides Superior Normal Tissue Sparing in Rat Lung Compared to Non-conventional Ultra-High Dose Rate (FLASH) Radiotherapy.

Authors:  Michael D Wright; Pantaleo Romanelli; Alberto Bravin; Geraldine Le Duc; Elke Brauer-Krisch; Herwig Requardt; Stefan Bartzsch; Ruslan Hlushchuk; Jean-Albert Laissue; Valentin Djonov
Journal:  Cureus       Date:  2021-11-06

3.  Synchrotron-generated microbeams induce hippocampal transections in rats.

Authors:  Erminia Fardone; Benoît Pouyatos; Elke Bräuer-Krisch; Stefan Bartzsch; Hervè Mathieu; Herwig Requardt; Domenico Bucci; Giacomo Barbone; Paola Coan; Giuseppe Battaglia; Geraldine Le Duc; Alberto Bravin; Pantaleo Romanelli
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

Review 4.  Microbeam radiation therapy - grid therapy and beyond: a clinical perspective.

Authors:  Elisabeth Schültke; Jacques Balosso; Thomas Breslin; Guido Cavaletti; Valentin Djonov; Francois Esteve; Michael Grotzer; Guido Hildebrandt; Alexander Valdman; Jean Laissue
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

5.  A preclinical microbeam facility with a conventional x-ray tube.

Authors:  Stefan Bartzsch; Craig Cummings; Stephan Eismann; Uwe Oelfke
Journal:  Med Phys       Date:  2016-12       Impact factor: 4.071

6.  Hybrid dose calculation: a dose calculation algorithm for microbeam radiation therapy.

Authors:  Mattia Donzelli; Elke Bräuer-Krisch; Uwe Oelfke; Jan J Wilkens; Stefan Bartzsch
Journal:  Phys Med Biol       Date:  2018-02-13       Impact factor: 3.609

7.  Perspectives for microbeam irradiation at the SYRMEP beamline.

Authors:  Elisabeth Schültke; Stefan Fiedler; Ralf Hendrik Menk; Felix Jaekel; Diego Dreossi; Katia Casarin; Giuliana Tromba; Stefan Bartzsch; Stephan Kriesen; Guido Hildebrandt; Fulvia Arfelli
Journal:  J Synchrotron Radiat       Date:  2021-02-15       Impact factor: 2.616

8.  A high-resolution dose calculation engine for X-ray microbeams radiation therapy.

Authors:  Sarvenaz Keshmiri; Sylvan Brocard; Raphaël Serduc; Jean-François Adam
Journal:  Med Phys       Date:  2022-04-12       Impact factor: 4.506

9.  Microbeam Irradiation as a Simultaneously Integrated Boost in a Conventional Whole-Brain Radiotherapy Protocol.

Authors:  Felix Jaekel; Elke Bräuer-Krisch; Stefan Bartzsch; Jean Laissue; Hans Blattmann; Marten Scholz; Julia Soloviova; Guido Hildebrandt; Elisabeth Schültke
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.